HeartSciences (NASDAQ:HSCS) reported fiscal first-quarter 2027 results with no meaningful revenue, a net loss of $3.2 million, and progress updates on its proposed business combination with Fortitude Mining Holdings.
Vera Therapeutics (NASDAQ:VERA) reported final Phase 3 ORIGIN 3 results showing TRUTAKNA (atacicept-vymj) stabilized kidney function and reduced disease progression over two years in adults with primary IgA nephropathy at risk of progression.
Connect Biopharma (NASDAQ:CNTB) reported preliminary topline Phase 2 results from the Seabreeze STAT Asthma study showing rademikibart improved lung function as an add-on treatment for acute asthma exacerbations with type 2 inflammation.
Rocket Pharmaceuticals (NASDAQ:RCKT) received alignment from the U.S. Food and Drug Administration on continued enrollment, dosing, and key design elements for its global Phase 2 pivotal trial of RP-A501 in patients with Danon disease.
Pulse Biosciences (NASDAQ:PLSE) completed enrollment in the PRECISE-BTN clinical study evaluating its nPulse Vybrance Percutaneous Electrode System for treating symptomatic benign thyroid nodules.
BioVie (NASDAQ:BIVI) reported topline Phase 2 ADDRESS-LC trial results for bezisterim in Long COVID, showing statistically significant improvements in pre-specified subgroups with higher baseline fatigue, cognitive impairment, and post-exertional malaise.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, an investigational RNA interference therapy designed to silence PCSK9 and APOC3 genes for patients with mixed hyperlipidemia.
Eli Lilly (NYSE:LLY) will present new clinical trial data on retatrutide, Foundayo (orforglipron), and eloraTZP at the European Association for the Study of Diabetes 2026 meeting in Milan from September 28 to October 2.
Strawberry Fields REIT (NYSE:STRW) completed the acquisition of a healthcare campus in Marshall, Missouri, adding a 60-bed hospital, a 99-bed skilled nursing facility, and a medical office building to its portfolio.
Summit Therapeutics (NASDAQ:SMMT) reported updated overall survival results from the global Phase III HARMONi clinical trial showing ivonescimab plus chemotherapy continued to demonstrate survival results in patients with EGFR-mutated advanced non-small cell lung cancer.
Allarity Therapeutics (NASDAQ:ALLR) received a Japanese patent for its stenoparib-specific DRP companion diagnostic, covering methods to identify patients likely to benefit from stenoparib treatment.
Abbott (NYSE:ABT) agreed to pay $385 million on September 14, 2026, to resolve government and civil claims connected to its 2022 powdered infant formula recall.
